Excellent
Mostly Aligned
Patient Risk:
Low
Summary
All substantive statements align with the provided FDA label regarding indication (adults with amenable GLA variants), mechanism (pharmacological chaperone), patient selection by in vitro/clinical genetics interpretation, dosing specifics, lack of contraindications, and the label-supported limitation to amenable variants. No direct contradictions were found.
Category Scores
Accurate Statements
Galafold (generic name: migalastat) is used for Fabry disease in certain patients.
Section 1: Indicated for adults with confirmed Fabry disease with an amenable GLA variant.
Galafold is marketed by Amicus Therapeutics.
Galafold is used in people with Fabry disease who have amenable mutations.
Section 1: amenable GLA variant based on in vitro assay data; Section 2.1 reiterates amenable GLA variant selection.
Migalastat helps certain Fabry disease-causing mutations fold correctly so the enzyme can reach lysosomes.
Section 12.1: migalastat reversibly binds alpha-Gal A, stabilizes it, and allows trafficking into the lysosome; amenable variants may be stabilized by migalastat.
Migalastat is not broadly effective for all mutations; benefit depends on whether a mutation is considered amenable.
Sections 1 and 2.1: treatment indicated for amenable GLA variants; Section 12.1: amenable variants may be stabilized by migalastat; Section 14 discusses efficacy in amenable variants and states non-amenable variants had no change.
Doctors determine amenability using genetic testing to identify the patient’s specific GLA mutation.
Section 2.1: Select adults with confirmed Fabry disease who have an amenable GLA variant interpreted by a clinical genetics professional in the clinical context of the patient.
Amenability is checked by whether the patient’s GLA variant is on a list of mutations expected to respond to migalastat.
Section 1: amenable GLA variant based on in vitro assay data; Section 2.1: amenable GLA variant interpreted by clinical genetics professional (consistent with use of in vitro amenability data to determine amenability).
Galafold is not for everyone with Fabry disease.
Sections 1 and 2.1: indicated only for adults with amenable GLA variants; excludes non-amenable variants from the indicated population.
Some people with Fabry disease are not candidates for Galafold because of mutation amenability.
Sections 1 and 2.1: indicated only with amenable GLA variants; Section 14: amenable variants show efficacy and non-amenable variants had no change.
Unsupported Statements
Galafold is marketed by Amicus Therapeutics.
The provided label excerpts do not include marketing/labeler information identifying the company.
Contradictions
Important Omissions
The label specifies dosing and administration details (123 mg orally once every other day; take at the same time of day; empty stomach; avoid caffeine 2 hours before and after; swallow whole; missed-dose instructions). None of the provided claims include these label-specific dosing/administration requirements.
Importance:
Moderate
The label includes specific guidance about uncertain clinical significance (VUS) and recommending consultation with a clinical genetics professional; the claims only generally reference amenability without reflecting the VUS/benign-context caution.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claims mostly reflect on-label patient selection (amenable GLA variants) and the labeled mechanism. However, missing label-specific dosing/administration and the VUS/benign-context selection nuance could contribute to inaccurate real-world use if implemented without additional label detail.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Some non-label claim (company marketing) is unsupported by the provided label excerpts; also key label dosing/administration details and the clinical-genetics/VUS nuance are omitted.
Suggested Improvement
Remove or verify the company marketing statement using label cover/labeler details, and add label-specified dosing/administration and the clinical genetics professional interpretation guidance (including VUS/benign context) if practical use instructions are being described.